TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03265964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uridine
Description: Uridine is the active treatment in this clinical trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study: NCT00717795

Intervention type: BEHAVIORAL
Intervention: interview and wait list
Description: Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
Study: NCT01142505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: 4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
Study: NCT01730716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human spinal cord stem cell implantation
Description: Human spinal cord stem cell implantation in ALS patients.
Study: NCT00152243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: uracil-tegafur 360 mg per square meter per day orally 16 months

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
Study: NCT01269619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic back support
Description: A dynamic back support which provides pressure on the lumbar without pressure on the abdomen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static back support
Description: A standard wrap-around sacro lumbar support
Study: NCT03963921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: Heterologous human adult liver-derived progenitor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: Heterologous human adult liver-derived progenitor cells
Study: NCT02878096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SK-1404
Description: In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
Study: NCT04736719

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference group
Study: NCT04056312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Memory retraining exercises
Description: Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group memory exercise training
Description: Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
Study: NCT02905357

Intervention type: DEVICE
Intervention: OCT
Description: Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.

Intervention type: OTHER
Intervention: CMR
Description: Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
Study: NCT00921258

Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years
Study: NCT00003190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Description: Given IV
Study: NCT01137656

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine and Blood
Description: The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
Study: NCT03859648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONEBRIDGE
Description: Bone Conduction Implant
Study: NCT03026283

Intervention type: DEVICE
Intervention: HeartFLow CT-FFR
Description: Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
Study: NCT04076436

Intervention type: OTHER
Intervention: Drug: Intravenous fosfomycin
Description: Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality

Intervention type: OTHER
Intervention: Drug: Intravenous quinolone or beta-lactam
Description: Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality
Study: NCT03450408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Method of placement of Foley bulb transcervical dilator
Description: This trial will assess two methods used to place a Foley bulb transcervical dilator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Method of placement of Foley bulb transcervical dilator
Description: This trial will assess two methods used to place a Foley bulb transcervical dilator.
Study: NCT05345366

Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable

Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable
Study: NCT02797145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin dose-adjusted
Description: Serum digoxin concentration : 0.5 to 0.9 nanogram/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard dose
Description: the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
Study: NCT00211432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension (15 mg)
Study: NCT04307524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic repair
Description: laparoscopic suture repair of cesarean scar niche
Study: NCT03977584

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [^18F]GTP1
Description: IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [^18F]GTP1
Description: IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
Study: NCT02375009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Description: laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
Study: NCT02877056

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
Study: NCT04232150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single-dose midazolam for sedation under spinal anesthesia.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-dose midazolam for sedation under spinal anesthesia.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia with no sedation.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
Study: NCT00446732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroSshield
Description: Attachment of the UroShield device to the external part of the urinary catheter
Study: NCT02720003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTX DCB
Description: Treatment with a drug-coated balloon
Study: NCT02603952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules orally BID from Day 1 to Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules orally BID from Day 1 to Day 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules orally BID from Day 1 to Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
Study: NCT04581538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention of parallel arm 2
Description: This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention of parallel arm 3
Description: Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed.
Study: NCT03763110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo Activated Disinfection
Description: Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic paste
Description: An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996
Study: NCT04148222

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT01890382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: 30 g in total; twice a day (morning and evening)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey plus creatine
Description: whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine supplementation
Description: 7.5 g/d in total; three times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein
Description: 30 g in total; twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 6.0 g in total; twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00846378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post conditioning
Description: after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care for STEMI
Description: Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
Study: NCT03997448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemiciclib 150mg PO
Study: NCT04241159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Young Plasma
Description: The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Young Plasma
Description: The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks.
Study: NCT04481971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose in capsules gelatin
Description: Tablets
Study: NCT00857636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy, health message
Description: The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
Study: NCT04307524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment in the form of combined hormonal contraception
Description: patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare
Study: NCT01653340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine
Description: http://nevro.com/corporate/system-us
Study: NCT04098796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
Study: NCT00786253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg on demand use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil daily dosing 10 mg
Study: NCT03336814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Administration of terlipressine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT03335683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenidase
Description: drug per os twice day for 7 days, or for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenidase
Description: drug per os twice day for 7 days, or for 10 days
Study: NCT00977613

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise counseling
Description: motivational counseling to exercise a minimum 18 metabolic hours per week
Study: NCT03678675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
Study: NCT04129112

Intervention type: DRUG
Intervention: We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening
Description: Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening

Intervention type: DRUG
Intervention: We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening
Description: Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
Study: NCT01141920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low threshold care
Description: Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stepped-based care
Description: Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
Study: NCT03033160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Ring
Study: NCT00240968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.